| Document |
Document Title |
|
WO/2011/150209 |
The present invention resides in the discovery that glucocorticoid receptor antagonists are effective for treating muscular dystrophy including type 1 or type 2 myotonic dystrophy. Treatment methods and kits are provided.
|
|
WO/2011/130877 |
A crystalline form of methylprednisolone aceponate monohydrate exhibits an X-ray powder diffraction pattern having characteristic peaks at the diffraction angles 2θ= of 8.6°, 12.2°, 13.6°, 15.3°, and 19.3°. The method for preparing...
|
|
WO/2011/087441 |
It is provided apharmaceutical composition comprising 3-beta-hydroxy-5-alpha- pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25°C and 0% at 37°C.In ad...
|
|
WO/2011/019821 |
Applicants have discovered a method for the stereoselective and regioselective synthesis of 3α-hydroxy, 3β-methyl-5α- pregnan-20-one (ganaxolone) comprising reacting 5α-pregnane-3,20-dione; with an organometallic methylating agent in...
|
|
WO/2011/019821 |
Applicants have discovered a method for the stereoselective and regioselective synthesis of 3α-hydroxy, 3β-methyl-5α- pregnan-20-one (ganaxolone) comprising reacting 5α-pregnane-3,20-dione; with an organometallic methylating agent in...
|
|
WO/2010/136940 |
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to th...
|
|
WO/2010/062562 |
The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid pharmaceutical compositions for use in treating inflammation and other diseases and disorders.
|
|
WO/2009/124300 |
The invention provides and describes solid state 17α-ethynyl-androst- 5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5- ene-3β,...
|
|
WO/2009/044251 |
The present invention relates to hydrocortisone derivatives, the method of production thereof and the therapeutic or cosmetic use thereof to combat hair loss or in the treatment of cutaneous physiopathologies.
|
|
WO/2009/032321 |
This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.
|
|
WO/2009/032321 |
This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.
|
|
WO/2009/022477 |
[PROBLEMS] To provide a polymer wherein a biologically active substance is distributed uniformly at a high density. [MEANS FOR SOLVING PROBLEMS] The problems can be solved by selecting and using polynorbornene as the polymer.
|
|
WO/2009/019138 |
The present invention refers to an enzymatic process for obtaining 17alpha-monoesters of cortexolone and/or its 9, 11-dehydroderivatives starting from the corresponding 17alpha, 21-diesters which comprises an enzymatic alcoholysis reacti...
|
|
WO/2009/019138 |
The present invention refers to an enzymatic process for obtaining 17alpha-monoesters of cortexolone and/or its 9, 11-dehydroderivatives starting from the corresponding 17alpha, 21-diesters which comprises an enzymatic alcoholysis reacti...
|
|
WO/2008/097442 |
This disclosure relates to a composition comprising pregnane derivatives according to Formula (I), or a salt, solvate or hydrate thereof, and to a pharmaceutically acceptable carrier or excipient. The composition may be used to lower glu...
|
|
WO/2008/067086 |
The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyper...
|
|
WO/2008/012833 |
The present invention provides an improved process for the preparation of 16-dehydropregenolone acetate [16-DPA], wherein pseudodiosgenin diacetate (PDA) is oxidized to diosone by catalytic amount of KMnO4 in the presence of a co oxidant...
|
|
WO/2007/026651 |
Disclosed is a novel therapeutic agent for hypertension. The therapeutic agent comprises a compound of the formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
|
|
WO/2007/008155 |
The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a P2X7 receptor antagonist, and a second active ingredient which is a corticosteroid, of use in the treatment of respirator...
|
|
WO/2007/004236 |
The administration of pharmaceuticals of drugs which are having less solubility, lower bioavailability, lower bioabsorbability, less rte of absorption has become a big challenge in day today life. Therefore anattempt has been made to pre...
|
|
WO/2006/088134 |
It is intended to provide a method of relieving or avoiding a steroid-induced increase in ocular tension which is caused by the administration of a steroid compound. Namely, a steroid-induced increase in ocular tension can be relieved or...
|
|
WO/2006/041121 |
It is intended to provide: a remedy and/or a preventive for a chronic skin disease which comprises, as the active ingredients, (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacologically acceptable salt thereof and (b) a steroid dr...
|
|
WO/2006/015081 |
Processes useful in the preparation of pharmaceutical compounds such as fulvestrant and processes for the preparation of fulvestrant.
|
|
WO/2005/115332 |
The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time...
|
|
WO/2005/095434 |
Disclosed is a method for producing a 5&agr -pregnane derivative represented by the general formula (II) below which is characterized by reacting a pregnane derivative represented by the general formula (I) below with a metal selected fr...
|
|
WO/2005/095433 |
Disclosed is a method for producing a 5&agr -pregnane derivative represented by the general formula (II) below which is characterized by reacting a pregnane derivative represented by the general formula (I) below with a metal selected fr...
|
|
WO/2005/095432 |
Disclosed is a method for producing a pregnane derivative represented by the general formula (III) below which is characterized by selectively reducing a carbon-carbon double bond of a 5&agr -pregnane derivative represented by the genera...
|
|
WO/2005/095431 |
Disclosed is a method for producing a mixture of 5&agr -pregnane derivatives represented by the general formulae (II) and (III) below which is characterized by reacting a pregnane derivative represented by the general formula (I) below w...
|
|
WO/2005/044759 |
The present invention provides acetalization process for preparation of 16,17-acetals of pregnane derivatives from corresponding 16,17-dihydroxy compounds in phosphoric acid.
|
|
WO/2004/094451 |
The invention relates to 8β-vinyl-11β-(&ohgr -substituted)alkyl-estra-1,3,5(10)-trienes of general formula (I), which have ERβ-antagonistic activity, methods for the production thereof, the intermediate products thereof, pharmaceutica...
|
|
WO/2004/089970 |
The present invention are two crystalline salts, 17&agr -acetoxy-21-methoxy-11ß-(4-,N,N-dimethylaminophenyl)-19 norpregna-4,9-diene-3,20-dione hydrochloride and 17&agr -acetoxy-21-methoxy-11ß-(4-,N,N-dimethylaminophenyl)-19 norpregna-4...
|
|
WO/2004/078774 |
Disclosed is a process for the synthesis of 17β-hydroxy-7&agr -methyl- 19-nor-17&agr -pregn-5(10)-ene-20-yne-3-one (tibolone, 11) and intermediates useful for the synthesis thereof: (11).
|
|
WO/2004/078102 |
A process for the sterilization of water insoluble solid medicinal substances is described.The process provides the sterilization of beclomethasone, which is suitable for pulmonary administration. In particular, the process is used in in...
|
|
WO/2004/074306 |
A continuous process for the preparation of 16&agr ,17&agr [(R)butylidenedioxy]-6&agr ,9&agr -difluoro-11β,21-dihydroxypregn-4-ene-3,20-dione (rofleponide) is disclosed.
|
|
WO/2004/066920 |
The present invention encompasses compounds of Formula (I) or ph armaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory dis...
|
|
WO/2004/067546 |
The invention relates to novel carboxylic-acid-ester-type tetraalkyl ammonium salts, the production thereof and the pharmaceutical use thereof in fungal and bacterial infections and as potential inhibitors in the biosynthesis of choleste...
|
|
WO/2004/052911 |
An improved stereoselective process for the preparation of 6&agr -fluoropregnane derivatives of formula (I), comprising the reaction of 3-benzoyloxy-&Dgr 3,5-pregnane derivatives of formula (II), with an electrophilic fluorination agent ...
|
|
WO/2004/047845 |
Compositions containing β2 adrenergic agonists in combination with carbonates and carbamates of the formula (I) are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilation and for treating rhinitis...
|
|
WO/2004/033478 |
A genus of 11,21-dihydroxypregna-1,4-diene-3,20-diones is disclosed, in which the 21-hydroxy is esterified with C8 to C24 hydrocarbon or the residue of misoprostol. The compounds are useful for treating rhinitis and asthma, particularly ...
|
|
WO/2004/021975 |
The invention relates to an improved process for producing pharmacologically active synthetic stereoisomeric mixture of guggulsterones (4) in the three steps. The mixture of guggulsterones consists of Z-guggulsterone [4,17(20)-trans-preg...
|
|
WO/2004/012742 |
The present invention is directed to the use of anercortave acetate or the alcohol thereof for the protection of visual acuity in patients with age related macular degeneration.
|
|
WO/2004/011663 |
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...
|
|
WO/2004/009527 |
The subject invention provides novel HMG-CoA-reductase inhibitors. In a preferred embodiment, the HMG-CoA reductase inhibitors of the subject invention can be deactivated to a primary inactive metabolite by hydrolytic enzymes. Compounds ...
|
|
WO/2003/097040 |
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokin...
|
|
WO/2003/092706 |
The present invention relates to the use of xanthan gum as re-epithelializing agent and, in particular, to a pharmaceutical formulation comprising xanthan gum as a re-epitheliazing active principle eventually mixed with hyaluronic acid. ...
|
|
WO/2003/070745 |
Carbonates and carbamates of the formula and related steroid carbonates and carbamates are disclosed. The compounds are useful for treating rhinitis and asthma, particularly by inhalation, and for treating inflammation, particularly by l...
|
|
WO/2003/063859 |
The present invention relates to the pharmaceutical use of selective estrogen receptor modulators (SERMs) alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation....
|
|
WO/2003/059931 |
The invention relates to a process for the preparation of 7&agr −methyl hydroxy steroids of the Formula I: (Formula I)&semi wherein R1 is hydrogen, methyl or C≡CH&semi R2 is (CH2)nOH, wherein n is 0, 1 or 2&semi by a copper mediated ...
|
|
WO/2003/051904 |
A process for producing a 21−hydroxypregnane derivative represented by the general formula (III), (III) characterized by protecting the 7−position hydroxy group of a compound represented by the formula (I) (I) and subsequently elimin...
|
|
WO/2003/047329 |
A method for producing a 6a-fluorinated corticosteroid or derivative thereof by reacting a17-hydroxy-21-ester epoxide of Formula (II) with a stereoselective fluorinating agent to stereoselectively form a 21-ester-17-hydroxy 6a-fluorinate...
|
